Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Dr Alice T Shaw, MDcorrespondencePress enter key for correspondence informationemailPress enter key to Email the author, Leena Gandhi, MD, Prof Shirish Gadgeel, MD, Gregory J Riely, MD, Jeremy Cetnar, MD, Howard West, MD, D Ross Camidge, MD, Prof Mark A Socinski, MD, Alberto Chiappori, MD, Tarek Mekhail, MD, Bo H Chao, MD, Hossein Borghaei, DO, Kathryn A Gold, MD, Ali Zeaiter, MD, Walter Bordogna, PhD, Bogdana Balas, MD, Oscar Puig, PhD, Volkmar Henschel, PhD, Prof Sai-Hong Ignatius Ou, MD on behalf of the study investigators

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002J...

Gadgeel SM1, Gandhi L2, Riely GJ3, Chiappori AA4, West HL5, Azada MC6, Morcos PN7, Lee RM7, Garcia L8, Yu L7, Boisserie F7, Di Laurenzio L7, Golding S7, Sato J9, Yokoyama S9, Tanaka T9, Ou SH10.

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment...

Natale R1, Blackhall F, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmüller C, Pinder-Schenck M, Mezger J, Danson S, Gadgeel SM, Summers Y, Callies S, André V, Das M, Lahn M, Talbot D.

Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed.

Patki M1, Gadgeel S, Huang Y, McFall T, Shields AF, Matherly LH, Bepler G, Ratnam M.